-
RBC: Perrigo's Near-Term Risk Lessens, But Long-Term Issues Persist
Friday, November 10, 2017 - 3:22pm | 468Read More...Perrigo Company plc Ordinary Shares (NYSE: PRGO) impressed investors with third-quarter earnings Thursday and issued encouraging guidance that led some of Wall Street's bears to revisit their thesis on the pharmaceutical manufacturer. The Analyst RBC Capital Markets' Randall...
-
How Pharmacy Benefit Managers Add To The Cost Of Your Prescription
Thursday, January 26, 2017 - 12:14pm | 685Read More...Notwithstanding the broader market rally, pharmacy benefit managers, or PBMs, saw weakness on Wednesday amid fears that President Donald Trump has his eyes trained on this space. The reason? Trump is apparently suspecting these companies are colluding with drug manufacturers in jacking up prices...
-
Argus Upgrades AstraZeneca To Buy, Says Discount Is Too Steep Against Pipeline Potential
Monday, August 29, 2016 - 10:39am | 274Read More...AstraZeneca plc (ADR) (NYSE: AZN) shares are currently trading at a discount to S&P 500 pharma companies. Argus’ John Eade believes the discount is too steep given the company’s pipeline potential. Eade upgraded the rating on the company to Buy with a price target of $38. Coping...
-
What Are The Best-Selling Drugs Of 2014?
Friday, October 3, 2014 - 11:34am | 759Read More...What are the top-selling pharmaceutical drugs of the year? While 2014 is not yet over, it's possible to explore to answer to this question after making a few educated assumptions. According to research from IMS Health, a healthcare services, information and technology provider, the top...
